Phase 3 N=4 Therapy to Elevate CD4 Counts in HIV-1 Disease
HIV Disease
Primary: CD4/CD8 Ratio — 0.44 Ratio
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=377 A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia
COVID-19 Pneumonia
Primary: Cumulative Proportion of Participants Who Died or Required Mechanical Ventilation by Day 28 — 12.04; 19.26 Percentage of Participants
Phase 3 N=29 Rhopressa for Corneal Edema Associated With Fuchs Dystrophy
Fuchs Endothelial Dystrophy
Primary: Change in Central Corneal Thickness — -23; -2 microns
Phase 3 N=999 Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma
Asthma
Primary: Baseline-adjusted Area Under the Serial FEV1-time Curve Calculated From Time Zero to 12 Hours (AUC0-12h) on Day 1 of Treatment — 4.03; 3.96 liters x hours
Phase 3 N=602 A Study of an Antibiotic Implant in General Surgical Subjects at Higher Risk for Surgical Wound Infection
Colorectal Surgery · Surgical Wound Infection
Primary: Number of Participants With Surgical Wound Infections From Surgery Through Post-operative Day 60 — 90; 63 Participants
Phase 3 N=1,861 Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19
COVID-19
Primary: Percent Change From Baseline in CRP Levels at Day 4 in Participants With Serum IL-6 Level Greater Than the ULN (Phase 2) — -0.20; -0.77; -0.78 Percent Change — p=<0.0001
Phase 3 N=120 Transversus Abdominis Plane Block in Microsurgical Breast Recon w/Abdominal Free Flap in Breast CA
Breast - Female
Primary: Post-operative Narcotic Usage — 139.3; 169.2 milligrams (mg)
Phase 3 N=352 Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
Cytomegalovirus (CMV)
Primary: Percentage of Participants Who Achieved Confirmed Clearance of Plasma Cytomegalovirus (CMV) Deoxyribonucleic Acid (DNA) (CMV Viremia Clearance) at End of Week 8 — 23.9…
Phase 3 N=606 Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024)
Pneumococcal Infections
Primary: Geometric Mean Concentration of Serotype-specific Immunoglobulin G - Schedule A: 7-11 Months — 2.47; 3.66; 2.65; 1.71 μg/mL
Phase 3 N=120 Ibuprofen With or Without Acetaminophen for Low Back Pain
Low Back Pain
Primary: Change in Functional Impairment as Measured by the Roland Morris Disability Questionnaire — 11.1; 11.9 units on a scale
Phase 3 N=673 An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension
Essential Hypertension
Primary: Change of the 24 Hour Mean Systolic Blood Pressure From Baseline (Day 1) to Week 12 — -8.86; -6.15 mm Hg — p=0.0025
Phase 3 N=1,235 Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects
Dermatitis · Dermatitis, Atopic · Eczema
Primary: Percentage of Participants With Loss of Response: Double-blind (DB) Period — 77.5; 39.6; 16.5 percentage of participants
Phase 3 N=1,272 Pyronaridine Artesunate (3:1) Versus Coartem® in P Falciparum Malaria Patients
Malaria
Primary: PCR-Corrected Adequate Clinical and Parasitological Response (ACPR) Rate on Day 28 — 99.5; 99.2 percentage of subjects — p=0.578
Phase 3 N=28 Peripheral Dopamine in Postural Tachycardia Syndrome
Postural Tachycardia Syndrome · Orthostatic Intolerance
Primary: 24 Hour Urinary Sodium Excretion During Treatment Normalized to Creatinine — 140; 132; 137; 154 Milliequivalents per gram (mEq/g)
Phase 3 N=83 Bupropion-Enhanced Contingency Management (CM) for Cocaine Dependence
Substance Abuse · Cocaine Dependence
Primary: Number of Cocaine Negative Urines — 70.6; 57.7; 4.2; 14.5 Mean percent negative urines — p=0.889